Skip to main content
main-content

Cardiovascular disorders

News

02-12-2020 | Older adults | News

Increasing comorbidity linked to poorer care quality for older people with diabetes

The quality of care among older adults with diabetes declines with increasing comorbidity and is particularly low for those with both osteoarthritis and major depression, population-based study data show.

02-04-2020 | Dapagliflozin | News

Dapagliflozin may reduce AF and flutter risk in type 2 diabetes

The sodium-glucose cotransporter 2 inhibitor dapagliflozin may reduce the risk for atrial fibrillation or atrial flutter in patients with type 2 diabetes by a fifth, a post-hoc analysis of the DECLARE-TIMI 58 trial suggests.

01-09-2020 | Stroke | News

REWIND supports stroke protective effect for GLP-1 receptor agonists

An exploratory analysis of stroke outcomes in the REWIND trial indicates that dulaglutide may reduce the incidence but not severity of ischemic stroke in people with type 2 diabetes.

Read more

Related topics

Specific

Opinion

08-06-2019 | SGLT2 inhibitors | Editorial | Article

Cardiorenal syndromes and SGLT2 inhibitor usage

Sanjay Kalra explores the intrinsic link between the cardiovascular and renal systems, focusing on whether the SGLT2 inhibitor class has a role to play in diabetic patients with cardiorenal comorbidity.

11-14-2018 | Cardiovascular outcomes | Editorial | Article

What have I learned from cardiovascular outcome trials?

Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future.

05-22-2018 | Nutritional management | Editorial | Article

UK nutrition guidelines for the prevention and management of diabetes: An update for primary care

Advisory Board member Pamela Dyson underlines the key features for healthcare professionals working in diabetes education, diabetes management, type 2 diabetes prevention, and cardiovascular risk reduction.

In depth

07-02-2019 | Dulaglutide | Podcast | Article

REWIND, DECLARE, and high-risk diabetes patients

How will the findings of the REWIND trial and the DECLARE-TIMI 58 renal outcomes analysis affect treatment decisions for high-risk diabetes patients without overt cardiovascular disease? medwireNews asks Kamlesh Khunti.

11-16-2018 | Dapagliflozin | Video | Article

Researcher comment: DECLARE-TIMI 58

DECLARE-TIMI 58 steering committee member John Wilding talks us through the trial's findings (5:49).

Journal articles and book chapters

12-13-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

11-21-2018 | Cardiovascular disorders | Review | Article

Unrecognised cardiovascular disease in type 2 diabetes: Is it time to act earlier?

Schernthaner G et al. Cardiovasc Diabetol 2018; 17: 145. doi: 10.1186/s12933-018-0788-7

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

Case reports

Image Credits